Physician profile
Abid Ali
NPI 1346250115
$4,516.09
in general payments reported to CMS, 2019-2025
37 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $766 · 2020: $338 · 2021: $1,542 · 2022: $1,337 · 2023: $189 · 2024: $344.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $533.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $533.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $649.06 | 2019-2023 | Vumerity |
| Supernus Pharmaceuticals, INC. | $515.07 | 2022-2024 | Qelbree |
| Novartis Pharmaceuticals Corporation | $474.51 | 2019-2022 | |
| Ucb, INC. | $328.66 | 2019-2022 | |
| Teva Pharmaceuticals USA, INC. | $325.71 | 2019-2022 | |
| Abbvie INC. | $189.16 | 2022-2023 | Duopa, Botox, Ubrelvy |
| Celgene Corporation | $173.69 | 2021-2024 | Zeposia |
| Alexion Pharmaceuticals, INC. | $166.03 | 2020-2022 | |
| Neurocrine Biosciences, INC. | $139.76 | 2021 | |
| Acorda Therapeutics, INC | $129.79 | 2019 | |
| Amgen INC. | $119.41 | 2021-2022 | |
| Lilly USA, LLC | $117.40 | 2019-2022 | |
| Mdd US Operations, LLC | $113.31 | 2019-2024 | Apokyn |
| Kyowa Kirin, INC. | $108.62 | 2019-2022 | |
| Livanova USA, INC. | $107.64 | 2020-2022 |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceutical Holding Company LTD. | $98.59 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $83.12 | 2020-2021 | |
| Genentech USA, INC. | $77.54 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $65.70 | 2022 | |
| Sk Life Science, INC. | $64.75 | 2021-2022 | |
| Biohaven Pharmaceuticals, INC. | $63.42 | 2021 | |
| Banner Life Sciences, LLC | $59.89 | 2022-2024 | |
| Acadia Pharmaceuticals INC | $38.56 | 2022-2023 | Daybue |
| Emd Serono, INC. | $37.32 | 2019 | |
| Adamas Pharmaceuticals, INC. | $32.29 | 2019-2021 | |
| Alnylam Pharmaceuticals INC. | $26.98 | 2019 | |
| Jazz Pharmaceuticals INC. | $24.70 | 2020 | |
| Horizon Therapeutics Plc | $23.40 | 2021 | |
| Avion Pharmaceuticals | $23.17 | 2022 | |
| Akcea Therapeutics, INC. | $22.68 | 2019 | |
| Allergan, INC. | $22.63 | 2021 | |
| Sunovion Pharmaceuticals INC. | $18.87 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $16.48 | 2022 | |
| Boston Scientific Corporation | $16.38 | 2024 | |
| Greenwich Biosciences, INC. | $15.38 | 2021 | |
| Eisai INC. | $13.81 | 2022 | |
| Mallinckrodt Enterprises LLC | $12.61 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Abid Ali listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.